MedTrace Logo

A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors

NCT06474455 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 156

Last updated 2026-05-11

No results posted yet for this study

Summary

This study is an open-label, multicenter Phase IB/II clinical trial to evaluate the safety, tolerability and efficacy of SHR-9839 for injection in combination with other antitumor therapies in patients with advanced solid tumors.

Conditions

Interventions

DRUG

SHR-9839 for Injection

SHR-9839 for injection.

DRUG

SHR-A1921 for Injection

SHR-A1921 for injection.

DRUG

SHR-A2009 for Injection

SHR-A2009 for injection.

DRUG

Almonertinib Mesilate Tablets

Almonertinib Mesilate Tablets.

DRUG

Pemetrexed Disodium for Injection

Pemetrexed Disodium for Injection.

DRUG

Carboplatin for injection

Carboplatin for injection.

DRUG

Paclitaxel injection

Paclitaxel injection.

DRUG

SHR-1316 Injection

SHR-1316 injection.

DRUG

SHR-9839 for Injection (sc)

SHR-9839 for Injection (sc).

Sponsors & Collaborators

  • Shanghai Hengrui Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-02
Primary Completion
2029-06-30
Completion
2029-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06474455 on ClinicalTrials.gov